Compass Therapeutics, Inc. (CMPX) Stock Grade

About Compass Therapeutics, Inc.'s fundamentals

Compass Therapeutics is a biotechnology company with a market capitalization of $199.9 million that reported a net loss in its latest annual statement, resulting in a zero net margin. The company experienced a complete decline in year-over-year revenue, dropping 100%, indicating either a pivot in business operations or discontinuation of previous revenue streams. The company does not currently pay a dividend and cannot be evaluated using traditional profitability metrics like price-to-earnings ratio or return on equity due to its loss-making status.